Aldosterone Synthase Inhibitors and the Treatment of Essential Hypertension.
作者信息
Gomez-Sanchez Celso E, Gomez-Sanchez Elise P
机构信息
G. V. (Sonny) Montgomery VA Medical Center, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Department of Pharmacology, University of Mississippi Medical Center, Jackson, MS 39216, USA.
出版信息
J Clin Endocrinol Metab. 2023 Jul 14;108(8):e638-e639. doi: 10.1210/clinem/dgad071.
Abstract
摘要
相似文献
1
Aldosterone Synthase Inhibitors and the Treatment of Essential Hypertension.醛固酮合成酶抑制剂与原发性高血压的治疗
J Clin Endocrinol Metab. 2023 Jul 14;108(8):e638-e639. doi: 10.1210/clinem/dgad071.
2
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.评估 Baxdrostat（一种用于治疗高血压的醛固酮合酶抑制剂）的 II 期结果。
Expert Opin Investig Drugs. 2023 Jul-Dec;32(11):985-995. doi: 10.1080/13543784.2023.2276755. Epub 2023 Nov 24.
3
[Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].基于187例原发性醛固酮增多症的回顾性分析的诊断与治疗结果
Orv Hetil. 2006 Jan 15;147(2):51-9.
4
Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.巴克斯洛他汀：一种用于治疗顽固性高血压的新型醛固酮合酶抑制剂。
Curr Probl Cardiol. 2023 Nov;48(11):101918. doi: 10.1016/j.cpcardiol.2023.101918. Epub 2023 Jul 2.
5
The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.选择性醛固酮合酶抑制剂巴多司他可显著降低顽固性高血压患者的血压。
Front Endocrinol (Lausanne). 2022 Dec 9;13:1097968. doi: 10.3389/fendo.2022.1097968. eCollection 2022.
6
Recent progress in the diagnosis and treatment of primary aldosteronism.原发性醛固酮增多症的诊治进展。
Hypertens Res. 2023 Jul;46(7):1738-1744. doi: 10.1038/s41440-023-01288-w. Epub 2023 May 17.
7
Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.醛固酮受体拮抗剂对原发性醛固酮增多症患者醛固酮/肾素比值的影响。
J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3655-e3664. doi: 10.1210/clinem/dgab290.
8
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.一项描述药物动力学特征，并证明醛固酮合酶抑制剂巴曲酶在健康志愿者中的安全性和选择性的 1 期、随机、双盲、多次递增剂量研究结果。
Hypertens Res. 2023 Jan;46(1):108-118. doi: 10.1038/s41440-022-01070-4. Epub 2022 Oct 20.
9
Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?醛固酮合酶的抑制作用：与盐皮质激素受体阻断相比，这是否具有优势？
Hypertens Res. 2023 Apr;46(4):1056-1057. doi: 10.1038/s41440-023-01188-z. Epub 2023 Jan 18.
10
Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.抗高血压药物对原发性高血压和原发性醛固酮增多症鉴别诊断中醛固酮和肾素浓度的影响。
Clin Endocrinol (Oxf). 2002 Oct;57(4):457-65. doi: 10.1046/j.1365-2265.2002.01613.x.
引用本文的文献
1
Exploring hypertension-linked diseases: a comprehensive review of innovative drug combinations with enhanced therapeutic potential.探索与高血压相关的疾病：对具有增强治疗潜力的创新药物组合的全面综述。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 31. doi: 10.1007/s00210-025-03819-3.
2
Evaluating the role of aldosterone synthesis on adrenal cell fate.评估醛固酮合成对肾上腺细胞命运的作用。
Front Endocrinol (Lausanne). 2024 Aug 7;15:1423027. doi: 10.3389/fendo.2024.1423027. eCollection 2024.
3
Challenges in Diagnosing and Managing the Spectrum of Primary Aldosteronism.原发性醛固酮增多症谱系诊断与管理中的挑战
J Endocr Soc. 2024 Jun 4;8(7):bvae109. doi: 10.1210/jendso/bvae109. eCollection 2024 May 23.
本文引用的文献
1
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.巴多司他治疗顽固性高血压的2期试验。
N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7.
2
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.一项描述药物动力学特征，并证明醛固酮合酶抑制剂巴曲酶在健康志愿者中的安全性和选择性的 1 期、随机、双盲、多次递增剂量研究结果。
Hypertens Res. 2023 Jan;46(1):108-118. doi: 10.1038/s41440-022-01070-4. Epub 2022 Oct 20.
3
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.库欣病患者服用奥昔布宁长期疗效：LINC 3 研究扩展。
Eur J Endocrinol. 2022 Sep 16;187(4):531-541. doi: 10.1530/EJE-22-0317. Print 2022 Oct 1.
4
Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data.醛固酮合酶抑制剂在心血管疾病中的应用：临床前、临床和计算数据的综合评价。
Pharmacol Res. 2021 Jan;163:105332. doi: 10.1016/j.phrs.2020.105332. Epub 2020 Dec 1.
5
The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study.原发性醛固酮增多症的未被识别流行率：一项横断面研究。
Ann Intern Med. 2020 Jul 7;173(1):10-20. doi: 10.7326/M20-0065. Epub 2020 May 26.
6
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.耐药性高血压的内分泌和血液动力学变化，以及螺内酯或阿米洛利对血压的反应：PATHWAY-2 机制子研究。
Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8. Epub 2018 Apr 11.
7
Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.大脑盐皮质激素受体在认知和心血管稳态中的作用
Steroids. 2014 Dec;91:20-31. doi: 10.1016/j.steroids.2014.08.014.
8
Effect of aminoglutethimide on blood pressure and steroid secretion in patients with low renin essential hypertension.氨鲁米特对低肾素性原发性高血压患者血压及类固醇分泌的影响。
J Clin Invest. 1978 Jul;62(1):162-8. doi: 10.1172/JCI109101.
Zotero 插件